Oncology strong for Chugai as Tamiflu boosts sales
This article was originally published in Scrip
Executive Summary
Roche's majority-owned Japanese operation, Chugai, saw strong growth in the first quarter on the back of oncology products from its parent and increased stockpiling of Tamiflu (oseltamivir).